The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)
Objective: To assess the efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in adult patients with moderate COVID-19 symptoms (hospitalized patients with COVID-19 pneumonia who were not admitted to an intensive care unit). Methods: We conducted a randomized, double blind, placebo-controlled,...
Saved in:
Main Authors: | M.Al Ghobain (Author), F. Rebh (Author), A. Saad (Author), A.H. Khan (Author), N. Mehyar (Author), A. Mashhour (Author), I. Islam (Author), Y. Alobaida (Author), A.S. Alaskar (Author), M. Boudjelal (Author), M.Al Jeraisy (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies
by: Nimer Mehyar
Published: (2023) -
Validated stability-indicating methods for the determination of zafirlukast in the presence of its alkaline hydrolysis degradation product
by: Amal M. Abou Al Alamein
Published: (2012) -
Novel Tetrazolium-Based Colorimetric Assay for Helicase nsp13 in SARS-CoV-2
by: Triet M. Pham, et al.
Published: (2024) -
Multi-stage structure-based virtual screening approach towards identification of potential SARS-CoV-2 NSP13 helicase inhibitors
by: Mahmoud A. El Hassab, et al.
Published: (2022) -
DNA helicases: expression, functions and clinical implications
by: Fumiaki Uchiumi
Published: (2015)